Li Jinze, Cui Shengyu, Li Yanqiu, Zhang Can, Chang Chao, Jian Fengzeng
Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing, China.
Spine Center, China International Neuroscience Institute (CHINA-INI), Beijing, China.
CNS Neurosci Ther. 2025 Feb;31(2):e70244. doi: 10.1111/cns.70244.
Spinal cord injury (SCI) is a complex central nervous system disorder characterized by multifaceted pathological processes, including inflammation, oxidative stress, programmed cell death, autophagy, and mitochondrial dysfunction. Sirtuin 1 (Sirt1), a critical NAD-dependent deacetylase, has emerged as a promising therapeutic target for SCI repair due to its potential to protect neurons, regulate glial and vascular cells, and optimize the injury microenvironment. However, the regulatory roles of Sirt1 in SCI are complex and challenging, as its effects vary depending on activation timing, expression levels, and cell types.
A systematic literature review was conducted using PubMed, Scopus, and Web of Science to identify studies investigating Sirt1 in SCI. Relevant publications were analyzed to synthesize current evidence on Sirt1's mechanisms, therapeutic effects, and challenges in SCI repair.
Sirt1 exerts broad regulatory effects across diverse pathological processes and cell types post-SCI. It promotes neuronal survival and axonal regeneration, modulates astrocytes and microglia to resolve inflammation, supports oligodendrocyte-mediated myelination, and enhances vascular endothelial function. Proper Sirt1 activation may mitigate secondary injury, whereas excessive or prolonged activation could impair inflammatory resolution or disrupt cellular homeostasis. This review highlights Sirt1 activation as potential therapies, but challenges include optimizing spatiotemporal activation and addressing dual roles in different cell types.
Targeting Sirt1 represents a viable strategy for SCI repair, given its multifaceted regulation of neuroprotection, immunomodulation, and tissue remodeling. However, translating these findings into therapies requires resolving critical issues such as cell type-specific delivery, precise activation timing, and dosage control. This review provides a theoretical foundation and practical insights for advancing Sirt1-based treatments for SCI.
脊髓损伤(SCI)是一种复杂的中枢神经系统疾病,其特征在于多方面的病理过程,包括炎症、氧化应激、程序性细胞死亡、自噬和线粒体功能障碍。沉默调节蛋白1(Sirt1)是一种关键的烟酰胺腺嘌呤二核苷酸(NAD)依赖性脱乙酰酶,由于其具有保护神经元、调节神经胶质细胞和血管细胞以及优化损伤微环境的潜力,已成为脊髓损伤修复中有前景的治疗靶点。然而,Sirt1在脊髓损伤中的调节作用复杂且具有挑战性,因为其作用因激活时间、表达水平和细胞类型而异。
使用PubMed、Scopus和Web of Science进行系统的文献综述,以确定研究Sirt1在脊髓损伤中的作用的研究。对相关出版物进行分析,以综合关于Sirt1在脊髓损伤修复中的机制、治疗效果和挑战的现有证据。
Sirt1在脊髓损伤后的各种病理过程和细胞类型中发挥广泛的调节作用。它促进神经元存活和轴突再生,调节星形胶质细胞和小胶质细胞以解决炎症,支持少突胶质细胞介导的髓鞘形成,并增强血管内皮功能。适当的Sirt1激活可能减轻继发性损伤,而过度或长期激活可能损害炎症消退或破坏细胞稳态。本综述强调Sirt1激活作为潜在治疗方法,但挑战包括优化时空激活以及解决其在不同细胞类型中的双重作用。
鉴于Sirt1对神经保护、免疫调节和组织重塑的多方面调节作用,靶向Sirt1是脊髓损伤修复的可行策略。然而,将这些发现转化为治疗方法需要解决诸如细胞类型特异性递送、精确激活时间和剂量控制等关键问题。本综述为推进基于Sirt1的脊髓损伤治疗提供了理论基础和实践见解。